Physician profile
Michael John Ferguson
NPI 1700873932
$1,916.51
in general payments reported to CMS, 2019-2025
22 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $67.11 · 2021: $95.20 · 2022: $444 · 2023: $348 · 2024: $383 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.92 | 2021-2025 | |
| Novo Nordisk INC | $325.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $136.91 | 2019-2021 | |
| Amgen INC. | $122.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $62.30 | 2023-2025 | Airsupra |
| Astellas Pharma US INC | $58.30 | 2024-2025 | Veozah |
| Pfizer INC. | $52.77 | 2019-2023 | |
| Boston Scientific Corporation | $48.83 | 2024 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.58 | 2019-2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $41.25 | 2023 | Qelbree |
| Allergan, INC. | $35.85 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $29.19 | 2025 | |
| Amarin Pharma, INC. | $27.34 | 2020 | |
| Noven Therapeutics, LLC | $18.81 | 2024 | Xelstrym |
| Janssen Pharmaceuticals, INC | $16.64 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.79 | 2023 | Arexvy, Shingrix |
| Upsher-Smith Laboratories LLC | $14.97 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.05 | 2023 | Livalo, Seglentis |
| Shire North American Group INC | $13.82 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.52 | 2019 | |
| Lilly USA, LLC | $11.52 | 2019 | |
| Melinta Therapeutics, LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.